Cargando…
Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology
In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabeti...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437198/ https://www.ncbi.nlm.nih.gov/pubmed/35896888 http://dx.doi.org/10.1007/s40123-022-00547-2 |
_version_ | 1784781531637612544 |
---|---|
author | Al Qassimi, Noura Kozak, Igor Al Karam, Maysoon Neri, Piergiorgio Aduriz-Lorenzo, Patricio M. Attawan, Alaa Awadalla, Mohamed El Khashab, Ahmed Abdul-Nabi, Mohamed Safar, Ammar Al Shamsi, Hanan Rao, Prasan Rao, Madhav Farid, Amr Gurbaxani, Avinash |
author_facet | Al Qassimi, Noura Kozak, Igor Al Karam, Maysoon Neri, Piergiorgio Aduriz-Lorenzo, Patricio M. Attawan, Alaa Awadalla, Mohamed El Khashab, Ahmed Abdul-Nabi, Mohamed Safar, Ammar Al Shamsi, Hanan Rao, Prasan Rao, Madhav Farid, Amr Gurbaxani, Avinash |
author_sort | Al Qassimi, Noura |
collection | PubMed |
description | In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabetic macular edema (DME). These published guidelines are based on evidence taken from the literature and published trials of therapies, and consensus opinion of a representative expert panel with an interest in this condition, convened by the Emirates Society of Ophthalmology. The aim is to provide evidence-based, clinical guidance for the best management of different aspects of DME, with a special focus on vision-threatening diabetic retinopathy. Treatment should be initiated in patients with best-corrected visual acuity 20/30 or worse, and/or features of DME as seen on optical coherence tomography (OCT) with central retinal thickness (CRT) of at least 300 μm or in symptomatic patients with vision better than 20/25, and/or CRT less than 300 μm where there are OCT features consistent with center-involving macular edema. The treatment of DME is effective irrespective of glycated hemoglobin (HbA1c) level, and treatment must not be denied or delayed in order to optimize systemic parameters. All ophthalmic treatment options should be discussed with the patient for better compliance and expectations. Non-center-involving DME can be initially observed until progression toward the center is documented. Macular laser no longer has a primary role in center-involving DME, and anti-vascular endothelial growth factor (anti-VEGF) therapy should be considered as first-line treatment for all patients, unless contraindicated. If anti-VEGF is contraindicated, a steroid dexamethasone implant can be considered for first-line treatment. Recommendations for the treatment of DME in special circumstances and in relapsing and refractory DME are also discussed. |
format | Online Article Text |
id | pubmed-9437198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-94371982022-09-03 Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology Al Qassimi, Noura Kozak, Igor Al Karam, Maysoon Neri, Piergiorgio Aduriz-Lorenzo, Patricio M. Attawan, Alaa Awadalla, Mohamed El Khashab, Ahmed Abdul-Nabi, Mohamed Safar, Ammar Al Shamsi, Hanan Rao, Prasan Rao, Madhav Farid, Amr Gurbaxani, Avinash Ophthalmol Ther Practical Approach In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabetic macular edema (DME). These published guidelines are based on evidence taken from the literature and published trials of therapies, and consensus opinion of a representative expert panel with an interest in this condition, convened by the Emirates Society of Ophthalmology. The aim is to provide evidence-based, clinical guidance for the best management of different aspects of DME, with a special focus on vision-threatening diabetic retinopathy. Treatment should be initiated in patients with best-corrected visual acuity 20/30 or worse, and/or features of DME as seen on optical coherence tomography (OCT) with central retinal thickness (CRT) of at least 300 μm or in symptomatic patients with vision better than 20/25, and/or CRT less than 300 μm where there are OCT features consistent with center-involving macular edema. The treatment of DME is effective irrespective of glycated hemoglobin (HbA1c) level, and treatment must not be denied or delayed in order to optimize systemic parameters. All ophthalmic treatment options should be discussed with the patient for better compliance and expectations. Non-center-involving DME can be initially observed until progression toward the center is documented. Macular laser no longer has a primary role in center-involving DME, and anti-vascular endothelial growth factor (anti-VEGF) therapy should be considered as first-line treatment for all patients, unless contraindicated. If anti-VEGF is contraindicated, a steroid dexamethasone implant can be considered for first-line treatment. Recommendations for the treatment of DME in special circumstances and in relapsing and refractory DME are also discussed. Springer Healthcare 2022-07-27 2022-10 /pmc/articles/PMC9437198/ /pubmed/35896888 http://dx.doi.org/10.1007/s40123-022-00547-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Practical Approach Al Qassimi, Noura Kozak, Igor Al Karam, Maysoon Neri, Piergiorgio Aduriz-Lorenzo, Patricio M. Attawan, Alaa Awadalla, Mohamed El Khashab, Ahmed Abdul-Nabi, Mohamed Safar, Ammar Al Shamsi, Hanan Rao, Prasan Rao, Madhav Farid, Amr Gurbaxani, Avinash Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title | Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title_full | Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title_fullStr | Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title_full_unstemmed | Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title_short | Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology |
title_sort | management of diabetic macular edema: guidelines from the emirates society of ophthalmology |
topic | Practical Approach |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437198/ https://www.ncbi.nlm.nih.gov/pubmed/35896888 http://dx.doi.org/10.1007/s40123-022-00547-2 |
work_keys_str_mv | AT alqassiminoura managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT kozakigor managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT alkarammaysoon managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT neripiergiorgio managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT adurizlorenzopatriciom managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT attawanalaa managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT awadallamohamed managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT elkhashabahmed managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT abdulnabimohamed managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT safarammar managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT alshamsihanan managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT raoprasan managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT raomadhav managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT faridamr managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT gurbaxaniavinash managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology AT managementofdiabeticmacularedemaguidelinesfromtheemiratessocietyofophthalmology |